Peritoneal Cancer Active Pharmaceutical Ingredient Selumetinib CAS 606143-52-6

Selumetinib Effect on Peritoneal Cancer 606143-52-6 Best Price 99% CAS 606143-52-6 Selumetinib Powder

Chemical name: Selumetinib
MF: C17H15BrClFN4O3
MW: 457.685
CAS: 606143-52-6
Appearance: White powder
Purity: 99%
Package: 100g/foil bag

Selumetinib is an orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK or MAPK/ERK kinase) 1 and 2. MEK 1 and 2 are dual specificity kinases that are essential mediators in the activation of the RAS/RAF/MEK/ERK pathway, are often upregulated in various cancer cells, and are drivers of diverse cellular responses, including proliferation. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers.

Selumetinib is under investigation for the treatment of Carcinoma, Thymic, Non-Small Cell Lung Cancer, and Carcinoma, Small Cell Lung. AZD6244 has been investigated for the treatment and basic science of Melanoma, Solid Tumours, Breast Cancer, Non Small Cell Lung Cancer, and Non Small Cell Lung Carcinoma, among others.

The gene BRAF is part of the MAPK/ERK pathway, a chain of proteins in cells that communicates input from growth factors. Activating mutations in the BRAF gene, primarily V600E (meaning that the amino acid valine in position 600 is replaced by glutamic acid), are associated with lower survival rates in patients with papillary thyroid cancer. Another type of mutation that leads to undue activation of this pathway occurs in the gene KRAS and is found in NSCLC. A possibility of reducing the activity of the MAPK/ERK pathway is to block the enzyme MAPK kinase (MEK), immediately downstream of BRAF, with the drug selumetinib. More specifically, selumetinib blocks the subtypes MEK1 and MEK2 of this enzyme.